Portfolio Lab

Baxter International Inc

  • Stock
  • Ticker BAX
  • ISIN US0718131099
  • NYSE

Health care · Medical technology · USA

$25.39 0.00%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Baxter International Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

BAXGlobal equities (VT)

$10,000 grew to $6,292. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −81.2% in 03/2026, measured from the peak in 04/2020. The old peak has not been reached again yet.

1-year return
+46.0%
5-year return p.a.
−18.8%
10-year return p.a.
−4.5%
Volatility p.a.
28.6%
Largest decline
−81.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue2,7532,6252,8102,8352,9742,7012,9602,976
Gross profit9598619919505778911,032994
Operating income-43558191172-72966217225
EBITDA-190305297262-489303311319
Net income-51212691-46-1,128-15126294
Earnings per share-1.000.250.18-0.09-2.20-0.030.240.57
Balance sheet
Total assets25,78221,30421,04621,06720,05519,84619,79119,414
Liabilities18,75814,25013,75313,85313,95313,83013,61212,939
Equity6,9647,0817,3207,2416,1296,0436,2066,502
Cash1,7642,2941,6861,7261,9662,0172,1501,975
Long-term debt13,180–––9,438–––
Cash flow
Operating cash flow488-193217237584213285558
Free cash flow488-193217237584213285558

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +47.3%, weakest 2022 at −39.6%. 4 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$0.57
30 Jul 2026$0.24
30 Apr 2026−$0.03
12 Feb 2026−$2.20
4 Nov 2025−$0.09
5 Aug 2025$0.18
6 May 2025$0.25
21 Feb 2025−$1.00
12 Nov 2024$0.27
6 Aug 2024−$0.61
2 May 2024$0.07
8 Feb 2024$0.48

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€12bn
Market cap in trading currency
$13.1bn
Enterprise value
$11.2bn
P/E
–
P/S
1.13
P/B
2.02
EV/Sales
0.96
EV/EBITDA
25.1
Earnings yield
–
FCF yield
12.5%

Results (last four quarters)

Revenue
$11.6bn
Gross profit
$3.49bn
EBITDA
$444m
Net income
−$723m
Earnings per share
−$1.42
Revenue per share
$22.44
Revenue growth
+5.0%
Earnings growth
–

Profitability

Gross margin
30.1%
Operating margin
-1.9%
Net margin
-6.2%
Return on equity
-10.5%
Return on assets
-3.7%

Balance sheet and cash flow

Cash
$1.98bn
Cash per share
$3.82
Financial debt
$0
Debt/equity %
0
Current ratio
1.79
Book value per share
$12.57
Operating cash flow
$1.64bn
Free cash flow
$1.64bn

Dividend

Dividend yield
0.16%
Dividend (12 months)
$0.04
Yield (12 months)
0.16%
Payout ratio
–
Ex-dividend date
28 Aug 2026

Shares and trading

Shares outstanding
517m
Volume
4.32m
Avg. volume 3 months
6.42m
Relative volume
0.7

Price and technicals

Price
$25.39
1 day
0.0%
52-week high
$28.35
52-week low
$15.80
Distance to 52-week high
−10.4%
Distance to 52-week low
+60.7%
Distance to 50-day line
+3.0%
Distance to 200-day line
+16.6%
RSI (14)
50
Volatility 1M
47.7%

Performance

1 week
−1.6%
1 month
−1.0%
3 months
−4.2%
6 months
+32.4%
YTD
+32.9%
1 year
+43.5%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has BAX performed since 11/2016?

$10,000 grew to $6,292 by 20 Nov 2026, which is −4.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is BAX?

Volatility was 28.6% per year, measured on monthly returns. The largest decline from a peak was −81.2%, with the low in 03/2026.

How does BAX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, BAX returned −4.5% at 28.6%. The correlation of monthly returns was 0.35; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Baxter International Inc (BAX): Return and risk